5 Top Biotech Stocks That Look Vulnerable in 2018
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.…
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.…
The BTD decision for voxelotor was based on clinical data submitted from a trio of studies. Source: BioSpace
Gene therapy treatment is a high risk, high reward venture, but the promises of a therapy developed through these programs could be life-changing for patients. Source: BioSpace
Cellectar Biosciences is closing its manufacturing operations and contracting them out. Source: BioSpace
For multiple perspectives on addressing this challenge, three respected individuals involved with the effort to bridge clinical research and clinical health care share their views. Source: BioSpace
Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers for the offering. Source: BioSpace
The FDA issued a warning letter to Prosana Distribuciones in Mexico City for serious GMP violations and for producing an adulterated drug product. Source: Drug Industry Daily
The Patient Engagement Collaborative is gearing up for a launch in early 2018. The new, external panel is being built by the FDA and the Clinical Trials Transformation Initiative (CTTI),…
The FDA turned down a request from Novo Nordisk to deny ANDAs referencing its liraglutide-containing drugs without comparative studies. Source: Drug Industry Daily
The offers underline Novo Nordisk's interest in expanding beyond diabetes and into the rare diseases market. Source: BioSpace